[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IL197574A0 - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions

Info

Publication number
IL197574A0
IL197574A0 IL197574A IL19757409A IL197574A0 IL 197574 A0 IL197574 A0 IL 197574A0 IL 197574 A IL197574 A IL 197574A IL 19757409 A IL19757409 A IL 19757409A IL 197574 A0 IL197574 A0 IL 197574A0
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
aripiprazole
compositions
exhibit
pharmaceutically acceptable
Prior art date
Application number
IL197574A
Other versions
IL197574A (en
Original Assignee
Zysis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37421592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL197574(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zysis Ltd filed Critical Zysis Ltd
Publication of IL197574A0 publication Critical patent/IL197574A0/en
Publication of IL197574A publication Critical patent/IL197574A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)

Abstract

An orally deliverable pharmaceutical composition provides controlled release of aripiprazole. The composition includes a therapeutically effective amount of aripiprazole and at least one pharmaceutically acceptable excipient. The compositions of the invention may exhibit one or more of the release profiles defined in the specification.
IL197574A 2006-09-26 2009-03-12 Orally deliverable pharmaceutical compositions for the controlled release of aripiprazole and use thereof in the preparation of medicaments IL197574A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0618879.1A GB0618879D0 (en) 2006-09-26 2006-09-26 Pharmaceutical compositions
PCT/GB2007/003677 WO2008038003A2 (en) 2006-09-26 2007-09-26 Pharmaceutical compositions of aripiprazole

Publications (2)

Publication Number Publication Date
IL197574A0 true IL197574A0 (en) 2009-12-24
IL197574A IL197574A (en) 2012-07-31

Family

ID=37421592

Family Applications (1)

Application Number Title Priority Date Filing Date
IL197574A IL197574A (en) 2006-09-26 2009-03-12 Orally deliverable pharmaceutical compositions for the controlled release of aripiprazole and use thereof in the preparation of medicaments

Country Status (13)

Country Link
US (2) US8575172B2 (en)
EP (1) EP2066325B1 (en)
JP (1) JP2010504950A (en)
KR (1) KR20090065514A (en)
AT (1) ATE540680T1 (en)
AU (1) AU2007301742B2 (en)
CA (1) CA2664455A1 (en)
DK (1) DK2066325T3 (en)
ES (1) ES2395119T3 (en)
GB (1) GB0618879D0 (en)
IL (1) IL197574A (en)
PT (1) PT2066325E (en)
WO (1) WO2008038003A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
MX2011000622A (en) 2008-07-16 2011-04-07 Richter Gedeon Nyrt Pharmaceutical formulations containing dopamine receptor ligands.
US8372808B2 (en) * 2008-10-31 2013-02-12 Wisconsin Alumni Research Foundation Suppression of glial fibrillary acidic protein
WO2010146872A1 (en) * 2009-06-19 2010-12-23 株式会社メドレックス Composition for external application comprising aripiprazole and organic acid as active ingredients
CN102670553A (en) * 2011-03-14 2012-09-19 北京天衡药物研究院 Venlafaxine hydrochloride osmotic pump controlled release tablet
US9066949B2 (en) 2011-03-21 2015-06-30 James Conour Compositions and methods for the treatment of catatonia
JOP20200109A1 (en) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd Injectable preparation
WO2013175508A2 (en) 2012-05-24 2013-11-28 Medreich Limited Stable pharmaceutical composition of aripiprazole
US9170264B2 (en) * 2013-03-15 2015-10-27 Ameritox, Ltd. Methods of monitoring for adherence to aripiprazole therapy
CN103393594A (en) * 2013-08-22 2013-11-20 万特制药(海南)有限公司 Novel aripiprazole preparation composition
US10525057B2 (en) * 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
CN103536594A (en) * 2013-10-21 2014-01-29 江苏亚虹医药科技有限公司 Application of G-protein-coupled receptor antagonist in preparing medicine for treating glutamate receptor high-expression tumor
US20190070174A1 (en) * 2016-03-10 2019-03-07 The Regents Of The University Of Michigan Methods of treating neurodegenerative diseases
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
HUP1700253A1 (en) 2017-06-13 2019-01-28 Richter Gedeon Nyrt Solid preparations for oral administration
AU2018378348B2 (en) 2017-12-05 2024-09-19 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
EP3720434A4 (en) 2017-12-05 2021-09-01 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
CN110025572A (en) * 2018-01-11 2019-07-19 四川科伦药物研究院有限公司 Lauroyl Aripiprazole suspension and preparation method thereof
CN116726169A (en) * 2018-05-04 2023-09-12 韩国原子力医学院 Radiation sensitivity enhancing composition comprising aripiprazole as active ingredient
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
BR112021024380A2 (en) * 2019-06-04 2022-04-19 Sunovion Pharmaceuticals Inc Modified release formulations and uses thereof
KR102525213B1 (en) 2021-01-13 2023-04-25 아주대학교산학협력단 Identifiable quick response(qr)-coded orodispersible films, and preparation method thereof using 3d printer

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2608788B2 (en) * 1988-10-31 1997-05-14 大塚製薬 株式会社 Schizophrenia remedy
US5178878A (en) * 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
GB9611328D0 (en) 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
US6024981A (en) * 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
CA2431041A1 (en) 2001-01-02 2002-07-11 Pharmacia & Upjohn Company New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
MY129350A (en) 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
DE60234873D1 (en) 2001-06-19 2010-02-04 Norbert Mueller Use of COX-2 inhibitors to treat affective disorders
SE0102887D0 (en) 2001-08-29 2001-08-29 Astrazeneca Ab New formulation
AR033485A1 (en) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd MEDICINAL SUBSTANCE OF ARIPIPRAZOL OF LOW HYGROSCOPICITY AND PROCESS FOR THE PREPARATION OF THE SAME
FR2834212B1 (en) 2001-12-27 2004-07-09 Besins Int Belgique USE OF IMMEDIATE RELEASE POWDER IN PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS
CA2475839A1 (en) 2002-02-08 2003-08-14 Abbott Laboratories Combination therapy for treatment of schizophrenia
US20060073516A1 (en) * 2002-03-28 2006-04-06 Yasuaki Ito Novel screening method
DE10224170A1 (en) 2002-05-31 2003-12-11 Desitin Arzneimittel Gmbh Retarded release pharmaceutical composition, obtained without use of organic solvents or water by densifying mixture of active agent and retarding polymer in heated rollers
EP1545618A1 (en) 2002-07-29 2005-06-29 Potomac, Pharma, LLC. Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic
CA2529857A1 (en) 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
CA2495864C (en) 2002-08-20 2011-09-27 Bristol-Myers Squibb Company Aripiprazole complex formulation and method
WO2004039320A2 (en) 2002-10-25 2004-05-13 Collegium Pharmaceutical, Inc. STEREOISOMERS OF p-HYDROXY-MILNACIPRAN, AND METHODS OF USE THEREOF
US7491726B2 (en) 2003-03-21 2009-02-17 Hetero Drugs Limited Crystalline forms of aripiprazole
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
US6987111B2 (en) 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
WO2005048979A2 (en) * 2003-10-06 2005-06-02 Torrent Pharmaceuticals Limited Pharmaceutical composition having casing with multiple micro tablets
CA2542836A1 (en) * 2003-10-21 2005-05-12 Alpharma, Inc. Pharmaceutical formulations containing quetiapine
AU2004285448C1 (en) * 2003-10-23 2021-08-19 Otsuka Pharmaceutical Co., Ltd. Controlled release sterile injectable aripiprazole formulation and method
DE10353196A1 (en) * 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Multilayer dosage form with a matrix influencing the delivery of a modulatory substance
PL1708790T3 (en) 2003-12-02 2010-10-29 Pharmaneuroboost N V Use of pipamperone and a d2-receptor antagonist or a serotonin/dopamin antagonist for the treatment of psychotic disorders
CA2550726A1 (en) 2003-12-16 2005-06-30 Teva Pharmaceutical Industries Ltd. Methods of preparing aripiprazole crystalline forms
WO2005082370A1 (en) 2004-01-29 2005-09-09 Pfizer Products Inc. Combinations of an atypical antipsychotic and an aminomethylpyridyloxymethyl/benzisoxazole azabicyclic derivatives for treating cns disorders
BRPI0510074A (en) * 2004-04-22 2007-10-16 Boehringer Ingelheim Int pharmaceutical compositions for the treatment of sexual disorders ii
BRPI0510942A (en) 2004-05-11 2007-07-17 Pfizer Prod Inc combination of atypical antipsychotics and 5-ht1b receptor antagonists
TWI338583B (en) 2004-05-20 2011-03-11 Otsuka Pharma Co Ltd Solid pharmaceutical formulation
WO2006000222A2 (en) 2004-06-24 2006-01-05 H. Lundbeck A/S The combination of an antipsychotic and a glycine transporter type i inhibitor for the treatment of schizophrenia
WO2006012237A2 (en) 2004-06-25 2006-02-02 Shanghai Institute Of Pharmaceutical Industry Aripiprazole crystaline forms and associated methods
GB0417702D0 (en) 2004-08-09 2004-09-08 Merck Sharp & Dohme New uses
EP1812396A1 (en) 2004-11-18 2007-08-01 Synthon B.V. Crystalline aripiprazole solvates
AU2005319367B2 (en) 2004-12-20 2012-05-24 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
WO2006096439A2 (en) 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
EP2783688A1 (en) 2005-03-17 2014-10-01 Synhton B.V. Pharmaceutical tablets of crystalline type ii aripiprazole
WO2007004061A1 (en) 2005-04-15 2007-01-11 Medichem, S.A. Syntheses and preparations of polymorphs of crystalline aripiprazole
HUP0500683A3 (en) 2005-07-14 2009-03-30 Egis Gyogyszergyar Nyilvanosan New arylpiprazole salts for producing pharmaceutical composition
US20070148100A1 (en) * 2005-09-15 2007-06-28 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
DE602006004694D1 (en) 2006-01-05 2009-02-26 Teva Pharma Wet granulation method for the preparation of pharmaceutical aripiprazole compositions
EP1808165B1 (en) 2006-01-05 2009-04-29 Teva Pharmaceutical Industries Ltd Dry formulations of aripiprazole
GB0618879D0 (en) * 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
US20100004262A1 (en) 2010-01-07
US20140044786A1 (en) 2014-02-13
WO2008038003A2 (en) 2008-04-03
DK2066325T3 (en) 2012-04-30
AU2007301742A1 (en) 2008-04-03
EP2066325B1 (en) 2012-01-11
CA2664455A1 (en) 2008-04-03
PT2066325E (en) 2012-04-13
ES2395119T3 (en) 2013-02-08
EP2066325A2 (en) 2009-06-10
AU2007301742B2 (en) 2013-05-02
US8575172B2 (en) 2013-11-05
IL197574A (en) 2012-07-31
GB0618879D0 (en) 2006-11-01
KR20090065514A (en) 2009-06-22
ATE540680T1 (en) 2012-01-15
WO2008038003A3 (en) 2008-06-26
JP2010504950A (en) 2010-02-18

Similar Documents

Publication Publication Date Title
GB0618879D0 (en) Pharmaceutical compositions
WO2007027527A3 (en) Isoindole-imide compounds and compositions comprising and methods of using the same
PL2046298T3 (en) Pharmaceutical dosage form containing pharmaceutically acceptable solubilizing composition
MX2009003038A (en) 5-substituted quinazolinone derivatives and compositions comprising and methods of using the same.
SG152240A1 (en) Pharmaceutical compositions comprising an amphiphilic starch
IL176519A0 (en) Directly compressible pharmaceutical composition for the oral administration of cci-779
MX2010004323A (en) Oral dosage forms comprising licarbazîžpine acetate.
MX2010007083A (en) Anti - retroviral combination.
UA93709C2 (en) 12-imidazolyl-1-dodecanol and use thereof in the preparation of pharmaceutical compositions
PL2205279T3 (en) Pharmaceutical combination of aliskiren and valsartan
ZA200805761B (en) Pharmaceutical composition for the treatment of nail disease
BRPI0816798A2 (en) compound, pharmaceutical composition, methods for inhibiting the action of glycogen synthase kinase-3, and for treating, preventing or ameliorating a disease, use of a compound, and article of manufacture
WO2005094810A3 (en) Novel pharmaceutical compositions
WO2007131070A3 (en) Compositions, dosage forms and methods of treating emesis
ZA200807486B (en) Medicament formulations comprising fluoroquinolones
MX2010001243A (en) Anti-inflammatory composition.
EP2004164A4 (en) Pharmaceutical composition for treating or preventing degenerative and inflammatory diseases
EP2231146A4 (en) Pharmaceutical composition for the treatment and prevention of glaucoma
WO2008004100A3 (en) Therapeutic compounds
WO2010079433A3 (en) Pharmaceutical composition comprising melogliptin
HK1105872A1 (en) Orally dispersible pharmaceutical composition and process for the preparation thereof
WO2010137040A3 (en) Novel pharmaceutical compositions of ranolazine
WO2008039894A3 (en) Atorvastatin pharmaceutical compositions
WO2007110765A3 (en) Processes for the preparation of octreotide
WO2011039675A3 (en) Latrepirdine transdermal therapeutic dosage forms

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed